Christina Ramsenthaler1,2, Pauline Kane3, Wei Gao3, Richard J Siegert3,4, Polly M Edmonds5, Stephen A Schey6, Irene J Higginson3. 1. Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Faculty of Life Sciences and Medicine, King's College London, London, UK. christina.ramsenthaler@kcl.ac.uk. 2. Department of Palliative Medicine, Munich University Hospital, Munich, Germany. christina.ramsenthaler@kcl.ac.uk. 3. Department of Palliative Care, Policy and Rehabilitation, Cicely Saunders Institute, Faculty of Life Sciences and Medicine, King's College London, London, UK. 4. Department of Psychology, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand. 5. Department of Palliative Care, King's College Hospital NHS Foundation Trust, London, UK. 6. Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
Abstract
OBJECTIVES: Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment-related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. METHODS: A systematic database and grey literature search were conducted in six databases. Random-effects meta-analysis with inverse variance weighting to pool prevalence data was performed. RESULTS: Thirty-six studies were included of which 34 studies (N = 3023) provided data for meta-analysis. Twenty-seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1-99.2%), pain (73%, 39.9-91.7), constipation (65.2%, 22.9-92.2) and tingling in the hands/feet with 53.4% (0.4-99.7). The most common problems were decreased physical functioning (98.9%, 98.2-99.3), decreased cognitive functioning (80.2%, 40-96.1) and financial difficulties (78.4%, 39.1-95.4). These problems were present in newly diagnosed to advanced disease stage. CONCLUSIONS: Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.
OBJECTIVES:Multiple myeloma (MM) is an incurable haematological disease. Due to novel agents, overall survival has improved in this group, yet there are no systematic reviews to understand the symptom profiles resulting from disease and treatment-related toxicities. We aimed to synthesise data on the prevalence of symptoms in patients with MM. METHODS: A systematic database and grey literature search were conducted in six databases. Random-effects meta-analysis with inverse variance weighting to pool prevalence data was performed. RESULTS: Thirty-six studies were included of which 34 studies (N = 3023) provided data for meta-analysis. Twenty-seven distinct symptoms were reported, with the majority of studies focusing on pain (n = 27), fatigue (n = 19) and problems with functioning (n = 15). The most prevalent symptoms were fatigue (98.8%, 95% CI 98.1-99.2%), pain (73%, 39.9-91.7), constipation (65.2%, 22.9-92.2) and tingling in the hands/feet with 53.4% (0.4-99.7). The most common problems were decreased physical functioning (98.9%, 98.2-99.3), decreased cognitive functioning (80.2%, 40-96.1) and financial difficulties (78.4%, 39.1-95.4). These problems were present in newly diagnosed to advanced disease stage. CONCLUSIONS: Optimal quality of life and good symptom management in this incurable disease can only be achieved by routinely assessing symptoms throughout the disease trajectory.
Authors: Matthew R LeBlanc; Rachel Hirschey; Ashley Leak Bryant; Thomas W LeBlanc; Sophia K Smith Journal: Qual Life Res Date: 2019-12-17 Impact factor: 4.147
Authors: Mona Kamal; Xin Shelley Wang; Qiuling Shi; Teresa M Zyczynski; Catherine Davis; Loretta A Williams; Hui-Kai Lin; Araceli Garcia-Gonzalez; Charles S Cleeland; Robert Orlowski Journal: Support Care Cancer Date: 2020-05-11 Impact factor: 3.603
Authors: Mary Slavcev; Allison Spinelli; Elisabeth Absalon; Tara Masterson; Christoph Heuck; Annette Lam; Erwin De Cock Journal: Clinicoecon Outcomes Res Date: 2021-06-08
Authors: Stefan Knop; Maria-Victoria Mateos; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ganna Usenko; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Losava; Tomoaki Fujisaki; Mamta Garg; Jianping Wang; Susan Wroblewski; Anupa Kudva; Katharine S Gries; John Fastenau; Jesus San-Miguel; Michele Cavo Journal: BMC Cancer Date: 2021-06-02 Impact factor: 4.430